Mechelen, Belgium; 14 January 2009 - Galapagos NV (Euronext: GLPG)
announced today achievement of multiple milestones under its alliance
with Janssen Pharmaceutica NV ('Janssen'). Through the achievement
of the milestone payments announced today Galapagos will receive a
total of ?3.75 million.
In October 2007, Galapagos announced an alliance agreement with
Janssen providing Janssen with option rights to acquire worldwide,
commercial licenses to novel small-molecules from up to 12 of
Galapagos' internal programs involving rheumatoid arthritis (RA)
therapeutic targets. The milestones announced today relate to
achievement of Proof of Principle for compounds developed against
Galapagos targets. The compounds demonstrated a reduction of an
inflammatory disease biomarker in inflamed joint tissue cultured from
collagen-induced arthritic mice. Showing a reduction in such a
disease marker is an important step in the development of a new drug,
indicating that the potential drug can have an impact on slowing or
reversing disease.
About Galapagos
Galapagos (Euronext Brussels: GLPG; Euronext Amsterdam: GLPGA; OTC:
GLPYY) is a drug discovery company with pre-clinical programs in bone
and joint diseases and bone metastasis. Its division BioFocus DPI
offers a full suite of target-to-drug discovery products and services
to pharmaceutical and biotech companies, encompassing target
discovery and validation, screening and drug discovery through to
delivery of pre-clinical candidates. BioFocus DPI also provides
adenoviral reagents for rapid identification and validation of novel
drug targets, compound libraries for drug screening as well as ADMET
products to select compounds. Galapagos currently employs 460 people
and operates facilities in six countries, with global headquarters in
Mechelen, Belgium. More information about Galapagos can be found at
www.glpg.com.
CONTACT
Galapagos NV
Graham Dixon, PhD
Senior Vice President Drug Discovery
+32 473 86 87 51
ir@glpg.com
This release may contain forward-looking statements, including,
without limitation, statements containing the words "believes,"
"anticipates," "expects," "intends," "plans," "seeks," "estimates,"
"may," "will," "could," "stands to," and "continues," as well as
similar expressions. Such forward-looking statements may involve
known and unknown risks, uncertainties and other factors which might
cause the actual results, financial condition, performance or
achievements of Galapagos, or industry results, to be materially
different from any historic or future results, financial conditions,
performance or achievements expressed or implied by such
forward-looking statements. Given these uncertainties, the reader is
advised not to place any undue reliance on such forward-looking
statements. These forward-looking statements speak only as of the
date of publication of this document. Galapagos expressly disclaims
any obligation to update any such forward-looking statements in this
document to reflect any change in its expectations with regard
thereto or any change in events, conditions or circumstances on which
any such statement is based, unless required by law or regulation.
This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.
Copyright © Hugin AS 2009. All rights reserved.